HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ling Gao Selected Research

Ramucirumab

2/2022Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies.
1/2022Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
1/2022RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
1/2021Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer.
11/2020Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings.
10/2020Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial.
1/2019Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
3/2018Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
1/2018Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.
12/2017Population pharmacokinetic meta-analysis of ramucirumab in cancer patients.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ling Gao Research Topics

Disease

94Neoplasms (Cancer)
07/2022 - 12/2005
25Inflammation (Inflammations)
02/2022 - 10/2005
25Hypothyroidism
01/2021 - 10/2009
22Insulin Resistance
11/2022 - 08/2005
18Squamous Cell Carcinoma of Head and Neck
03/2022 - 12/2012
16Neoplasm Metastasis (Metastasis)
03/2022 - 08/2006
16Carcinogenesis
01/2022 - 08/2006
15Non-alcoholic Fatty Liver Disease
01/2022 - 01/2014
15Type 2 Diabetes Mellitus (MODY)
01/2022 - 10/2005
14Obesity
04/2021 - 02/2007
13Stomach Neoplasms (Stomach Cancer)
08/2021 - 10/2011
12Atherosclerosis
02/2022 - 05/2004
12Ischemia
01/2022 - 01/2006
12Cardiovascular Diseases (Cardiovascular Disease)
11/2021 - 10/2007
12Hypertension (High Blood Pressure)
11/2021 - 01/2012
12Reperfusion Injury
01/2021 - 08/2007
11Infarction (Infarctions)
01/2021 - 01/2012
10Carcinoma (Carcinomatosis)
01/2022 - 04/2010
10Myocardial Infarction
01/2021 - 06/2013
10Hypoxia (Hypoxemia)
01/2021 - 01/2008
8Fibrosis (Cirrhosis)
11/2022 - 08/2011
8Adenocarcinoma
02/2022 - 11/2013
8Colorectal Neoplasms (Colorectal Cancer)
01/2021 - 07/2015
7Merkel Cell Carcinoma
11/2022 - 01/2014
7Cognitive Dysfunction
01/2022 - 01/2020
7Pain (Aches)
12/2021 - 11/2009
7Breast Neoplasms (Breast Cancer)
10/2021 - 08/2008
7Hypercholesterolemia
01/2019 - 01/2007
6Dyslipidemias (Dyslipidemia)
01/2022 - 05/2014
6Nasopharyngeal Carcinoma
01/2022 - 10/2016
6Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 01/2014
6COVID-19
10/2021 - 01/2020
6Alzheimer Disease (Alzheimer's Disease)
10/2021 - 01/2020
6Hyperglycemia
05/2021 - 09/2003
6Heart Failure
01/2019 - 01/2008
6Goiter
01/2014 - 06/2007
6Graves Disease (Basedow Disease)
01/2014 - 06/2007
5Mitochondrial Diseases (Mitochondrial Disease)
10/2022 - 04/2009
5Lymphatic Metastasis
03/2022 - 10/2011
5Type 1 Diabetes Mellitus (Autoimmune Diabetes)
01/2022 - 04/2013
5Hepatocellular Carcinoma (Hepatoma)
01/2021 - 11/2014
5Infections
11/2019 - 08/2006
4Hypertrophy
11/2022 - 07/2007
4Papillary Thyroid Cancer
06/2022 - 03/2020
4Liver Diseases (Liver Disease)
05/2022 - 01/2020
4Pathologic Processes
03/2022 - 01/2016
4Uterine Cervical Neoplasms (Cancer of the Cervix)
12/2021 - 10/2018
4Hypertriglyceridemia
11/2021 - 04/2014
4Body Weight (Weight, Body)
11/2021 - 09/2003
4Hyperlipidemias (Hyperlipidemia)
11/2021 - 02/2007
4Neutropenia
09/2021 - 01/2017
4Diabetes Mellitus
01/2021 - 07/2006
4Diabetic Retinopathy (Retinopathy, Diabetic)
01/2021 - 09/2003
4Brain Edema (Cerebral Edema)
01/2021 - 10/2016

Drug/Important Bio-Agent (IBA)

44Proteins (Proteins, Gene)FDA Link
10/2022 - 01/2006
25Glucose (Dextrose)FDA LinkGeneric
11/2022 - 09/2003
24RamucirumabIBA
02/2022 - 01/2014
23LipidsIBA
11/2022 - 07/2007
23Biomarkers (Surrogate Marker)IBA
11/2022 - 10/2011
20Circular RNAIBA
06/2022 - 01/2019
19MicroRNAs (MicroRNA)IBA
03/2022 - 03/2011
16Insulin (Novolin)FDA Link
01/2022 - 08/2005
13Thyrotropin (Thyroid-Stimulating Hormone)FDA Link
02/2022 - 10/2010
13CholesterolIBA
10/2021 - 07/2007
13Triglycerides (Triacylglycerol)IBA
09/2021 - 04/2009
11Messenger RNA (mRNA)IBA
01/2021 - 01/2006
11CytokinesIBA
01/2021 - 10/2011
11Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2021 - 06/2007
9Long Noncoding RNAIBA
08/2021 - 01/2018
8Biological ProductsIBA
01/2021 - 09/2008
8Pharmaceutical PreparationsIBA
01/2021 - 01/2014
8Blood Glucose (Blood Sugar)IBA
12/2020 - 04/2010
8Retinaldehyde (Retinal)IBA
01/2020 - 09/2003
7oxidized low density lipoproteinIBA
01/2021 - 04/2014
7Small Interfering RNA (siRNA)IBA
01/2021 - 01/2009
6Paclitaxel (Taxol)FDA LinkGeneric
02/2022 - 10/2014
6Therapeutic UsesIBA
01/2022 - 02/2016
6Cisplatin (Platino)FDA LinkGeneric
01/2022 - 05/2014
6PlatinumIBA
01/2022 - 01/2014
6Streptozocin (Streptozotocin)FDA Link
01/2021 - 09/2003
6Peptides (Polypeptides)IBA
01/2020 - 04/2010
6Insulin Glargine (Lantus)FDA Link
01/2018 - 01/2012
6Ethanol (Ethyl Alcohol)IBA
05/2012 - 08/2005
5AntioxidantsIBA
10/2022 - 02/2007
5Apolipoproteins E (ApoE)IBA
01/2022 - 01/2019
5Competitive Endogenous RNAIBA
12/2021 - 01/2020
5Thyroid HormonesIBA
01/2020 - 05/2012
5Thyroxine (Levothyroxine)FDA LinkGeneric
01/2020 - 04/2014
5Monoclonal AntibodiesIBA
01/2017 - 01/2014
5Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
12/2016 - 01/2014
4Anti-Bacterial Agents (Antibiotics)IBA
01/2022 - 11/2019
4Amyloid (Amyloid Fibrils)IBA
01/2022 - 01/2020
4Peroxisome Proliferator-Activated Receptors (PPAR)IBA
10/2021 - 07/2008

Therapy/Procedure

39Therapeutics
04/2022 - 12/2005
14Drug Therapy (Chemotherapy)
01/2022 - 11/2013
10Radiotherapy
07/2022 - 07/2010
7Moxibustion
12/2021 - 08/2013
6Ligation
01/2022 - 06/2007
6Aftercare (After-Treatment)
12/2021 - 01/2014
6Transplantation
01/2020 - 01/2006